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Abstract
Background—The nociceptin/orphanin-FQ (NOP; or opioid-receptor-like (ORL1)) receptor is 
localized in the mesolimbic reward pathway and has been suggested to play a role in feeding, 
mood, stress, and addiction. Since its deorphanization in 1995, there has been a clear dichotomy in 
the literature regarding whether an agonist or antagonist would provide therapeutic benefit. 
Specifically, literature reports indicate that NOP receptor antagonists produce efficacy in animal 
models of hyperphagia and antidepressant-like activity, whereas NOP agonists produce anxiolytic-
like effects and dampen reward/addiction behaviors including ethanol consumption.
Methods—We characterize here the potent, orally-bioavailable NOP antagonist, LY2940094, in 
rodent models of ethanol consumption, including ethanol self-administration, progressive ratio 
operant self-administration, stress-induced reinstatement of ethanol-seeking, and in vivo 
microdialysis in the nucleus accumbens.
Results—LY2940094 dose-dependently reduced homecage ethanol self-administration in 
Indiana Alcohol-Preferring (P) and Marchigian Sardinian Alcohol-Preferring (msP) rats, without 
affecting food/water intake or locomotor activity. Reduced ethanol intake in P rats did not show 
significant tolerance over 4 days of subchronic dosing. LY2940094 attenuated progressive ratio 
operant responding and breakpoints for ethanol in P rats. Moreover, stress-induced reinstatement 
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of ethanol-seeking in msP rats was completely blocked by LY2940094. Furthermore, LY2940094 
blocked ethanol-stimulated dopamine release in response to ethanol challenge (1.1 g/kg, IP).
Conclusions—Our findings demonstrate for the first time that blockade of NOP receptors 
attenuates ethanol self-administration and ethanol-motivated behaviors, stress-induced ethanol-
seeking, and ethanol-induced stimulation of brain reward pathways in lines of rats that exhibit 
excessive ethanol consumption. Results suggest that LY2940094 may have potential therapeutic 
utility in treating alcohol addiction.
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1. Introduction
The peptide neurotransmitter nociceptin/orphanin-FQ (N/OFQ) and the receptor to which it 
binds (NOP) are localized throughout the mesocorticolimbic reward pathway and related 
areas (for example, central nucleus of the amygdala, bed nucleus of the stria terminalis, 
medial prefrontal cortex, ventral tegmental area, lateral hypothalamus, nucleus accumbens) 
which are critical mediators in motivated behaviors and addiction (Neal et al., 1999a, Neal et 
al., 1999b, Witkin et al., 2014, Koob et al., 2014). Although classified within the opioid 
family, N/OFQ does not bind classical mu, kappa, and delta opioid receptor subtypes (MOP, 
KOP, and DOP, respectively) with appreciable affinity, nor do classical opioid receptor 
agonists bind to the NOP receptor (Meunier et al., 1995, Reinscheid et al., 1995). Preclinical 
research supports that selective modulation of NOP receptor signaling may have potential 
therapeutic benefit in a number of clinical indications including obesity, pain, mood, 
addiction, cardiovascular control and immunity (Lambert, 2008, Witkin et al., 2014).
Peptide and non-peptide NOP receptor agonists have consistently been reported to regulate 
drug reward and drug-seeking behaviors associated with opiates, psychostimulants and 
ethanol (reviewed in (Witkin et al., 2014)). With respect to ethanol-mediated behaviors, 
NOP agonists attenuate conditioned place preference, ethanol self-administration, and 
ethanol-seeking behaviors in rat lines genetically-selected for high alcohol preference, 
including the Marchigian Sardinian Alcohol-Preferring (msP) and Indiana Alcohol-
Preferring (P) rats, as well as ethanol-dependent Wistar rats and Naval Medical Research 
Institute (NMRI) mice (Ciccocioppo et al., 2004, Ciccocioppo et al., 1999, Economidou et 
al., 2006, Economidou et al., 2008, Kuzmin et al., 2003, Kuzmin et al., 2007, de Guglielmo 
et al., 2015). The attenuation of ethanol self-administration and ethanol-motivated behaviors 
in these lines is presumed to be related to suppression of dopamine synthesis and release 
(Olianas et al., 2008, Murphy et al., 1996).
Since the deorphanization of the NOP receptor in 1995, a clear dichotomy has emerged in 
the literature regarding whether an agonist or antagonist would provide therapeutic benefit. 
Specifically, NOP receptor antagonists and NOP receptor knockout mice have been reported 
to produce efficacy in animal models of obesity and antidepressant-like activity, whereas 
NOP agonists have been reported to produce efficacy in animal models of reward/addiction 
and anxiolytic-like efficacy (Gavioli and Calo, 2013, Witkin et al., 2014, Rizzi et al., 2007, 
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Gavioli and Calo, 2006). Given the extant overlap of brain areas involved in the regulation of 
mood, reward, and food intake, this dichotomy has been difficult to reconcile.
We recently discovered a selective, orally-bioavailable NOP antagonist (LY2940094; 
compound 36 in (Toledo et al., 2014)) with high affinity (Ki = 0.105 nM) and antagonist 
potency (Kb = 0.166 nM) at NOP receptors (Statnick et al., 2016). Consistent with its 
antagonist pharmacological profile, LY2940094 potently inhibits excessive feeding 
behaviors in rodents (Statnick et al., 2016), demonstrates antidepressant-like efficacy in 
rodent models, and antidepressant efficacy in patients with major depressive disorder 
(Witkin et al., under review),(Post et al., 2015). Importantly, hypophagic and antidepressant-
like efficacy of LY2940094 in rodent models was lost in mice lacking NOP 
receptors(Statnick et al., 2016),(Witkin et al., under review). Because literature reports 
consistently indicated that NOP receptor agonists attenuated ethanol-motivated behaviors, 
we tested LY2940094 to determine its propensity to facilitate or exacerbate ethanol self-
administration and ethanol-seeking behaviors. In contrast to expectations based upon 
literature findings, we report herein for the first time that NOP receptor antagonism is also 
sufficient to attenuate ethanol drinking, seeking, and relapse.
2. Materials and Methods
2.1 Animals
Female Alcohol-Preferring (P) rats (generously supplied by the Indiana University School of 
Medicine and maintained at Taconic Inc. (Germantown, NY; 250–320 g) and male 
Marchigian Sardinian Alcohol-Preferring (msP) rats obtained from the University of 
Camerino (Marche, Italy; 400–450 g) were used in the ethanol experiments. Male Sprague-
Dawley rats obtained from Taconic Farms (Germantown, NY) weighing 260 – 300 g were 
used in the microdialysis experiment. For the homecage ethanol self-administration 
experiments, rats were individually-housed on a 12-hr light:dark cycle with food, water, and 
ethanol available ad libitum. For the operant ethanol experiments, rats were pair-housed on a 
12-hr light:dark cycle with food and water available ad libitum in the homecage. All 
experiments were conducted in compliance with the NIH Guide for the Care and Use of 
Laboratory Animals under protocols approved and monitored by a local animal care and use 
committee.
2.2 Drugs and reagents
[2-[4-[(2-Chloro-4,4-difluorospiro[5H-thieno[2,3-c]pyran-7,4′-piperidine]-1′-yl)methyl]-3-
methylpyrazol-1-yl]-3-pyridyl]methanol (LY2940094; (Toledo et al., 2014)) was synthesized 
at Lilly Research Laboratories (Madrid, Spain). Naltrexone HCl and yohimbine HCl were 
purchased from Sigma-Aldrich (St. Louis, MO and Milan, Italy, respectively). 95% Ethanol 
was diluted to 15% (v/v) in tap water for experiments in P rats and 10% (v/v) in distilled 
water for experiments in msP rats. LY2940094 was dissolved in 20% Captisol in 25 mM 
phosphate buffer (pH 3, adjusted for L-tartaric acid salt weight), and administered orally in a 
volume of 2–3 ml/kg. Yohimbine and naltrexone were dissolved in distilled water and 
injected IP and PO, respectively (1 ml/kg). Solutions were prepared fresh daily.
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2.3 Homecage Ethanol Self-Administration
Female P rats were individually-housed with ad libitum access to regular rat chow (Harlan 
Teklad Diet #2014), water, and 15% (v/v) ethanol in water. Consistent with literature 
indicating that this genetically-selected line exhibits high alcohol preference (Waller et al., 
1982), mean baseline ethanol intake was approximately 4.2 g/kg over the dark phase of the 
light:dark cycle (lights off at 4:00 pm) prior to initiation of the study. For the first 
experiment, rats (n = 9) received acute oral administration of vehicle, 10 mg/kg naltrexone, 
or 3, 10, or 30 mg/kg LY2940094, 5 min before onset of the dark phase, using a within-
subjects counterbalanced, Latin-square design (3–4 day washout between subsequent doses). 
In a separate experiment, rats (n = 19) received 4 daily oral doses of either vehicle or 30 
mg/kg LY2940094, 5 min before onset of the dark phase, in a between-subjects design. 
Voluntary consumption of ethanol, water, and food in both experiments was continuously 
monitored for the duration of the 12 hr dark phase after each dose, using a force transduction 
monitoring system (TSE Systems, Bad Homburg, Germany, as previously described 
(Rorick-Kehn et al., 2014)). At the same time, homecage locomotor activity was monitored 
using infrared sensors located on top of each cage (TSE Systems).
Male msP rats (n = 10) were individually-housed with ad libitum access to regular chow 
(Harlan Teklad Diet #2014), water and 10% (v/v) ethanol in water. Mean baseline ethanol 
intake was approximately 5–6 g/kg/day prior to initiation of the study. Rats received vehicle, 
3, or 30 mg/kg LY2940094 (PO) in a within-subjects, counterbalanced design, 60 min before 
onset of the dark cycle. Voluntary consumption of ethanol and water was measured at 2, 8, 
or 24 hr after dosing by recording volume of intake from graduated cylinders, as previously 
described (Economidou et al., 2006). Voluntary consumption of chow was measured at the 
same time points by weighing the food basket.
2.4 Progressive ratio operant responding for ethanol
Female P rats (n = 13) were pair-housed with chow and water available ad libitum except 
during the training and test sessions. One subject was excluded after box-plot analysis (JMP; 
SAS Institute, Inc., Cary, NC) determined this subject to be a significant outlier. Rats were 
trained to self-administer 15% ethanol (v/v) in 0.1 mL increments in standard rat operant 
chambers (Med-Associates, St. Albans, VT), starting with a fixed-ratio 1 schedule of 
reinforcement and slowly transitioning to a progressive ratio schedule. Rats were maintained 
on an arithmetic progressive ratio operant schedule with counterbalanced active and inactive 
levers as previously described (Rorick-Kehn et al., 2014). Briefly, response requirements 
were increased by 2 after every 3 reinforcements received. Because previous analysis 
demonstrated that P rats in this assay drank most of their alcohol during the first 15–20 min, 
the rats were removed from the operant chambers after 30 min and returned to their 
homecages. Breakpoints were measured as the highest fixed-ratio (FR) response requirement 
reached (breakpoint) during the 30-min session. Ethanol-seeking was defined as the number 
of responses on the alcohol-associated lever. After stable performance was achieved, rats 
were acclimated to the dosing procedures and then received oral doses of vehicle, 3, 10, or 
30 mg/kg LY2940094 (PO), or 10 mg/kg naltrexone (PO), 60 min prior to the operant 
session, using a within-subject counterbalanced, Latin-square design, with 3–4 days washout 
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between subsequent doses. Performance was monitored on non-drug days to confirm stable 
baseline performance.
2.5 Stress-induced reinstatement to ethanol-seeking
Male msP rats (n = 30) were individually-housed with food and water available ad libitum 
except during the training and test sessions. Experiments were conducted in standard rat 
operant chambers housed within sound-attenuating cubicles (Med-Associates, St. Albans, 
VT), as previously described (Ciccocioppo et al., 2004). During daily 30-min operant 
sessions, rats were trained to self-administer a 10% (v/v) ethanol solution under a fixed-
ratio-1 schedule of reinforcement, in which each response resulted in the delivery of 0.1 mL 
ethanol, followed by a 5-sec time out period, signaled by illumination of a 5W house light. 
Once stable baseline responding was achieved, rats were subjected to 30-min extinction 
sessions. During extinction sessions, all procedures were the same, except lever responses 
were no longer reinforced. After lever responses were extinguished, msP rats were subjected 
to a stress-induced reinstatement test conducted under the same extinction conditions, except 
that rats received the pharmacological stressor, yohimbine (2 mg/kg IP), 30 min before the 
session. Once stable baseline extinction responding was recovered following the previous 
yohimbine challenge, rats were randomly divided into 3 groups (N=10/group) and pretreated 
with LY2940094 (0, 3 or 10 mg/kg, PO) 60 min before the reinstatement test (30 min before 
yohimbine).
2.6 In vivo microdialysis
In vivo microdialysis studies were conducted in male Sprague-Dawley rats with guide 
cannulae (Bioanalytical Systems Inc, West Lafayette, IN) implanted in the Nucleus 
Accumbens (NAcc) as previously described (Rorick-Kehn et al., 2014). A 5 μM 
concentration of nomifensine was perfused via reverse microdialysis for all treatment groups 
to facilitate detection of extracellular dopamine levels. Reverse microdialysis of nomifensine 
was previously demonstrated to increase local concentrations of dopamine in the NAcc 
without altering evoked release of dopamine (Cenci et al., 1992). Importantly, all groups 
were treated with nomifensine, so any effects on dopamine levels related to the small local 
concentrations of nomifensine would be the same across all treatment groups. Rats received 
vehicle or 30 mg/kg LY2940094 (PO) prior to vehicle or ethanol challenge (1.1 g/kg, IP, 
administered as 15% v/v in 0.9% NaCl in a volume of 2.9 mL per rat). When LY2940094 
was administered alone, it was given 10 min into the 4th sample (0-min time point). When 
administered in combination with ethanol, it was given 10 min into the 1st sample (−60 min 
time point). Ethanol was administered 10 min into the 4th sample (i.e., at the 0-min time 
point). All data are presented as the mean + SEM for n = 4–6 rats per group. Probe 
placements were verified histologically, but histology samples were not archived.
3. Results
3.1 NOP Antagonist LY2940094 Attenuates Ethanol Self-Administration in Indiana Alcohol-
Preferring (P) and Marchigian Sardinian Alcohol-Preferring (msP) Rats
The effect of LY2940094 on ethanol self-administration, at doses that fully saturate NOP 
receptors (Toledo et al., 2014), was assessed in P rats. The mu-preferring opioid receptor 
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antagonist naltrexone was included as a comparator. Following acute dosing, a significant 
main effect of dose was observed on ethanol self-administration during the first 3 hr of the 
dark cycle [F(4,32) = 4.43, p < 0.02; Fig 1A]. Post-hoc analyses revealed that ethanol self-
administration was significantly attenuated in both naltrexone- (10 mg/kg) and LY2940094-
treated (30 mg/kg) groups (p < 0.05 vs. vehicle; Dunnett’s). No significant effects were 
observed on food or water intake or locomotor activity during the first 3 hr of the dark cycle 
(all p’s > 0.05; data not shown). Consistent with the pharmacokinetic and receptor 
occupancy profiles, the significant reduction of ethanol intake was maintained over the entire 
12-hr dark cycle in the LY2940094-treated group [F(4,32) = 4.94, p < 0.001], but not the 
naltrexone-treated group [p > 0.05; Fig 1B]. Post-hoc analyses revealed a significant effect 
of the 30 mg/kg dose of LY2940094 (p < 0.05 vs. vehicle; Dunnett’s). Neither LY2940094 
nor naltrexone significantly altered food or water intake (p’s > 0.05; Fig 1C). Neither 
LY2940094 nor naltrexone affected homecage locomotor activity (p’s > 0.05; data not 
shown).
In a subsequent study in Indiana P rats, LY2940094 (30 mg/kg) significantly decreased 
ethanol intake relative to vehicle control over 4 consecutive days of daily administration 
[Interaction: F(4,60) = 3.82, p < 0.01; Main Effect of Treatment: F(1,15) = 17.98, p < 0.001; 
Fig 1D], demonstrating lack of tolerance. Posthoc t-tests tests confirmed a significant effect 
of LY2940094 on each of the four active treatment days (all p’s < 0.002). Water and food 
intake were unaffected by LY2940094 in this experiment (p’s > 0.05; data not shown). 
Locomotor activity was also unaffected by subchronic administration of LY2940094 (p > 
0.05; data not shown).
LY2940094 dose-dependently reduced homecage ethanol self-administration in msP rats 
[F(2,18) = 27.78, p < 0.001; Fig 2A]. Post-hoc analysis revealed a significant reduction in 
voluntary ethanol consumption in the 30 mg/kg LY2940094 group at 2, 8 and 24 hr (all ps < 
0.01). As shown in Fig 2, the lower dose (3 mg/kg), significantly reduced ethanol drinking 
only at the 24-hr time point (p < 0.05), whereas no effect at the 3 mg/kg dose was observed 
at 2 and 8 hr post-dose. Consumption of chow diet was not significantly affected by drug 
treatment [p > 0.05; Fig 2B]. Results showed a slight trend toward an increase in water 
intake (Fig 2C) after drug treatment, but the effect was not statistically significant [p > 0.05].
3.2 LY2940094 Reduces the Motivation to Consume Ethanol and Ethanol-Seeking in P Rats
Oral administration of LY2940094 attenuated operant ethanol self-administration behavior 
maintained on a progressive ratio schedule in P rats. LY2940094 dose-dependently reduced 
the motivation to consume ethanol, as indicated by reduced breakpoints in drug-treated rats 
[F(4,55) = 7.5, p < 0.001; Fig 3A]. Posthoc tests indicated significant effects at both the 30 
mg/kg LY2940094 and 10 mg/kg naltrexone doses (p < 0.05). Reduced motivation for 
ethanol was also reflected by a significant reduction in the total number of lever presses on 
the active lever [F(4,55) = 5.2, p = 0.001; Fig 3B], which was reduced by about 50% during 
the 30-min operant session. Posthoc tests indicated that both LY2940094 (30 mg/kg) and 
naltrexone (10 mg/kg) reduced active lever presses (p < 0.05). LY2940094 did not alter 
responding on the inactive lever (lever not producing ethanol) [p=0.68; mean ±SEM inactive 
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lever presses: vehicle = 3.58 ± 1.15; 3 mg/kg = 2.92 ± 0.70; 10 mg/kg = 6 ± 2.25; 30 mg/kg 
= 6.17 ± 2.82; NTX = 5.17 ± 1.38].
3.3 LY2940094 Robustly Blocks Stress-Induced Reinstatement to Ethanol-Seeking in msP 
Rats
During the extinction phase, rats that were previously responding for ethanol at asymptotic 
levels (mean ±SEM lever presses: active lever, 49.6 ±1.9; inactive lever, 1.3 ±0.2) reduced 
their responding on the alcohol-associated lever to a mean of less than 10 responses per 
session (Fig 4; “Ext”). Administration of the pharmacological stressor and anxiety-
provoking agent, yohimbine (2 mg/kg, IP), significantly reinstated responding on the lever 
that previously delivered ethanol [Fig 4; F(1,18) = 10.36, p < 0.01]. Pre-treatment with 
LY2940094 significantly attenuated yohimbine-induced reinstatement [F(2,27) = 18.2, p < 
0.0001; Fig 4]. Post-hoc analysis revealed a significant inhibition of reinstatement by both 3 
and 30 mg/kg doses of LY2940094 (***p < 0.001). Responses on the inactive lever were 
unaffected by LY2940094 [p > 0.05; data not shown], indicating a behaviorally-specific 
effect of LY2940094 on yohimbine-elicited reinstatement of alcohol-seeking.
3.4 LY2940094 Blocks Ethanol-Stimulated Dopamine Release in the Nucleus Accumbens
Figure 5 shows the time course for changes in extracellular dopamine levels in the NAcc in 
response to ethanol challenge (1.1 g/kg, IP). The figure inset shows a summary comparison 
of the effects of the four treatment groups using the average post-injection dopamine 
response over 120 min. ANOVA revealed an overall significant difference between groups 
[(F(3,17) = 4.603, p < 0.02]. Subsequent pairwise comparisons demonstrated a significant 
ethanol-stimulated increase in extracellular dopamine levels (“Vehicle+Vehicle vs Vehicle
+EtOH” group; t(10) = 2.42, p < 0.05), that was fully prevented by pretreatment with 30 
mg/kg LY2940094 (“Vehicle+EtOH” vs “LY+EtOH”: t(9) = 3.10, p < 0.02; “Vehicle
+Vehicle” vs “LY+EtOH”: p > 0.05).
LY2940094, per se, neither increased nor decreased extracellular dopamine levels when 
administered alone (“LY2940094+Vehicle” vs “Vehicle+Vehicle”: p > 0.05).
4. Discussion
The current study provides the first in vivo evidence that blockade of endogenous N/OFQ 
signaling by oral administration of a NOP receptor antagonist attenuates or prevents ethanol 
intake, motivation to consume ethanol, and stress-induced relapse to ethanol-seeking in 
animal models. The importance and novelty of these findings can be contextualized by the 
large literature documenting that NOP receptor agonists also produce these ethanol-
attenuating effects and that the effects of agonists can be prevented by NOP receptor 
antagonists (c.f., overview and discussion in (Witkin et al., 2014); (Zaveri, 2011)).
LY2940094 is a potent and selective NOP receptor antagonist, with a Ki = 0.105 nM and a 
Kb = 0.166 nM and no agonist efficacy at concentrations up to 10 μM in CHO cells 
recombinantly expressing human NOP receptors (Statnick et al., 2016). The doses of 
LY2940094 used in the current study were based on receptor occupancy data; specifically, a 
10 mg/kg PO dose of LY2940094 yielded 62% NOP receptor occupancy in the brain (Toledo 
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et al., 2014). In the current study, LY2940094 dose-dependently reduced homecage ethanol 
self-administration in both P and msP rats, without affecting food or water intake or general 
locomotor activity, an effect that was maintained without evidence of tolerance for up to 4 
days of subchronic dosing (Figures 1 and 2).
We also report here that LY2940094 reduced the motivation to consume ethanol, as 
indicated by decreased progressive ratio operant responding and breakpoints for ethanol 
(Arnold and Roberts, 1997) in Indiana P rats. Additionally, LY2940094 completely blocked 
the ability of the alpha2 adrenoreceptor antagonist, yohimbine (a known anxiogenic agent 
and pharmacological stressor), to reinstate ethanol-seeking in msP rats, even at the lowest 
dose tested (3 mg/kg). The current results are paradoxical considering nearly two decades of 
research indicating that NOP agonists reduce the reinforcing and motivating effects of 
ethanol and block stress-induced reinstatement to ethanol-seeking (Ciccocioppo et al., 
1999), (Ciccocioppo et al., 2004),(Ciccocioppo et al., 2014),(Martin-Fardon et al., 2000). 
The mechanism by which LY2940094 blocked stress-induced reinstatement and motivation 
to consume ethanol is unknown, but the data are consistent with recent data showing that 
LY2940094 produced anxiolytic-like efficacy in preclinical models (Witkin et al., under 
review). It is interesting to note that, although the level of reinstatement following 
yohimbine was moderate, LY2940094 showed 10-fold greater potency for blocking this 
behavior relative to efficacy in other models reported herein that did not involve stress.
The suppression of ethanol self-administration and ethanol-motivated behaviors by 
LY2940094 reported here are similar to those reported previously using peptide and non-
peptide NOP receptor agonists (Ciccocioppo et al., 1999), (Kuzmin et al., 2007), 
(Ciccocioppo et al., 2004). Therefore, the current results raise the question: how do NOP 
antagonists produce similar effects as those previously reported for NOP agonists? Our 
current working hypothesis of the comparable ethanol-attenuating effects of NOP receptor 
agonists and antagonists is that agonists may produce desensitization and internalization of 
NOP receptors when administered in vivo, therefore reducing expression of NOP receptors 
at the plasma membrane which are available to bind N/OFQ agonists, thus resulting in a 
“functional” receptor blockade. Indeed, multiple labs have demonstrated rapid and robust 
receptor desensitization and internalization in vitro in response to the endogenous ligand as 
well as to small molecule synthetic agonists (Corbani et al., 2004, Dautzenberg et al., 2001, 
Spampinato et al., 2007). For example, the small molecule NOP agonist, Ro 64-6198, 
produced sustained desensitization and internalization of NOP receptors expressed in 
recombinant cells, which was prevented by both low temperature and hyperosmolar sucrose 
conditions that are known to prevent receptor internalization (Dautzenberg et al., 2001). Full 
recovery of NOP receptor binding sites was observed 24 hr after treatment in that study, 
consistent with canonical agonist-mediated regulation and trafficking. In another study, 
when monensin was used to block intracellular protein transport and inhibit receptor 
recycling, the proportion of membrane-expressed receptors in a desensitized state was 
increased (Spampinato and Baiula, 2006). Although NOP agonist-induced receptor 
desensitization and internalization still needs to be demonstrated in vivo, the initial findings 
reported here lead us to speculate that the efficacy of the agonists reported in the literature 
may be related to the reduced availability, and attenuated endogenous signaling, of the NOP 
receptor upon agonist exposure, thus producing a “functional” blockade of NOP receptors 
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after sub-chronic administration. This hypothesis is indirectly supported by published data 
indicating that acute administration of NOP agonists in vivo was either not effective or even 
sometimes increased ethanol self-administration (Ciccocioppo et al., 1999), whereas 
repeated administration of the agonists was required to reliably attenuate ethanol-motivated 
behaviors (Ciccocioppo et al., 1999, Economidou et al., 2006, Economidou et al., 2008),
(Ciccocioppo et al., 2014), suggesting sustained agonist-induced receptor desensitization 
and internalization in vivo. In contrast, LY2940094 acutely blocks Gi/o-coupled signaling of 
the NOP receptor (Toledo et al., 2014), (Statnick et al., 2016), presumably without triggering 
receptor internalization and recycling to the plasma membrane, although this has proven 
very difficult to measure in native tissue ex vivo preparations. Relatedly, one might also 
anticipate that chronic administration of a NOP antagonist may lead to compensatory 
upregulation of NOP receptors, possibly leading to tolerance. Our results provide 
preliminary evidence for lack of tolerance after subchronic dosing; however, additional work 
will be required to explore the effects of chronic administration.
An alternative explanation to the receptor desensitization and internalization hypothesis is 
that agonists and antagonists of NOP receptors may produce different patterns of activation 
or inhibition in different brain areas relevant to reward and addiction. That is, perhaps the 
volume of distribution of LY2940094 across relevant reward-related brain areas is different 
than the volume of brain distribution of the agonists, and the differential modulation of NOP 
receptors in different brain areas could potentially explain the paradoxical results reported 
herein. However, distribution patterns of NOP receptor expression (in the unblocked 
condition) reported in nonhuman primate positron-emission-tomography (PET) studies 
using the NOP agonist PET ligand 11C-NOP-A (Kimura et al., 2011) and the NOP 
antagonist PET ligand 11C-(S)-10c (Pike et al., 2011) were remarkably similar to each other 
in rhesus monkey, and both were strikingly similar to that reported in humans with 11C-
NOP-A (Lohith et al., 2012) and 11C-LY2959530 (Post et al., 2014). Therefore, it is unlikely 
that differential distribution of NOP agonists and antagonists in various reward-related brain 
regions can explain the anomalous findings reported here. Another alternative hypothesis is 
that the agonists and antagonists bind different splice variants of the NOP receptor, thus 
leading to differential pharmacology. Previous studies have reported evidence that the rat 
NOP receptor appears to be alternatively spliced and that the splice variants displayed 
differential tissue distribution (Curro et al., 2001). In that study, three different splice 
variants were detected in rat brain tissue. However, a later study assessing human tissue 
reported no evidence for expression of alternative splice variants in human brain tissue, the 
ultimate target of interest (Berthele et al., 2003). Thus, even if splice variants existed in the 
rodent, yielding differential pharmacology with different ligands, it is unlikely that would 
translate into observable differences in human pharmacology. Regardless, the possibility that 
different NOP receptor splice variants exist in the rodent which may contribute to 
differential pharmacology cannot be completely excluded with the current data. A third 
alternative hypothesis to explain similar effects produced by NOP agonists and antagonists is 
ligand-biased signaling (Kenakin, 2011). It is possible that NOP antagonists, or LY2940094 
in particular, exhibit biased signaling which leads to functional activation of similar 
intracellular signaling cascades as produced by NOP agonists. Indeed, a recent report 
provided the first evidence that NOP agonists MCOPPB and NNC 63-0532 exhibit biased 
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signaling for G-protein versus arrestin recruitment, and that simple mutations of the NOP 
antagonist J-113,397 resulted in partial agonist activity in vitro (Chang et al., 2015). 
However, we did not observe agonist activity in vitro with LY2940094 at concentrations up 
to 10 μM (Statnick et al., 2016). Further work will be required to determine the mechanism 
by which NOP agonists and antagonists produce similar efficacy in animal models of 
ethanol-motivated behaviors.
The ethanol-dampening effects of LY2940094 reported here were apparently NOP receptor-
mediated and specific to ethanol self-administration rather than reflecting a nonspecific 
effect on consummatory or locomotor behaviors, as food/water consumption and locomotor 
activity were not affected in the same rats (Figures 1 and 2). Moreover, in a previous study, 
LY2940094 reduced hyperphagic food intake in several preclinical models, without affecting 
normal food consumption, and the efficacy was NOP receptor-mediated, as evidenced by the 
lack of effect in mice lacking NOP receptors (Statnick et al., 2016). Moreover, we 
previously demonstrated that, over the dose range tested, LY2940094 selectively occupies 
NOP receptors in the brain and inhibits NOP agonist-mediated decreases in body 
temperature (Toledo et al., 2014),(Statnick et al., 2016). Therefore, we are fairly confident 
that the effects produced by LY2940094 reported here were mediated by NOP receptor 
antagonism.
It has been well-established that drugs abused by humans, including ethanol, stimulate 
dopamine release, particularly in the nucleus accumbens (Di Chiara and Imperato, 1988). 
We replicate those findings here, showing that IP-administered ethanol stimulated dopamine 
release when administered alone. Importantly, LY2940094 completely blocked the IP-
ethanol-stimulated dopamine release, without directly affecting dopamine release on its own 
(Figure 5). Since the ethanol was administered IP, blockade of ethanol-stimulated dopamine 
release by LY2940094 was independent of changes in ethanol consumption and, therefore, 
not likely confounded by nonspecific changes in motivation or reward or motor effects. 
Importantly, LY2940094 did not stimulate dopamine release in the nucleus accumbens when 
administered alone, suggesting reduced propensity for abuse potential. This neurochemical 
evidence supports the behavioral results and provides a possible mechanism for the 
reduction of ethanol drinking by NOP antagonists; specifically, attenuation of the reinforcing 
effects of ethanol (Weiss and Koob, 2001). As with the behavioral studies, the 
neurochemical data were not anticipated, considering others have reported that N/OFQ 
suppressed dopamine release in the nucleus accumbens (Murphy et al., 1996) (Koizumi et 
al., 2004a) and that NOP antagonists UFP-101 and Compound B (chemical name: 1-[(3R,
4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-
benzimidazol-2-one) blocked the dopamine-suppressing effects of N/OFQ (Koizumi et al., 
2004b, Koizumi et al., 2004a). Additional work will have to be conducted to fully clarify the 
mechanisms through which NOP receptors regulate mesolimbic dopamine transmission.
5. Conclusions
The current study provides the first in vivo evidence that a NOP receptor antagonist, such as 
the potent and selective NOP antagonist LY2940094, attenuates ethanol self-administration 
and motivation to consume ethanol in animal models of alcoholism. Moreover, we 
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demonstrate that LY2940094 blocks stress-induced reinstatement to ethanol-seeking and 
ethanol-stimulated dopamine release in the nucleus accumbens, a critical locus in the brain 
reward pathway (Koob et al., 2014). The data suggest that NOP receptor antagonists, such as 
LY2940094, may have therapeutic benefit in the treatment of alcohol dependence and 
alcohol use disorders, as evidenced by efficacy in multiple behavioral and neurochemical 
preclinical models of alcoholism.
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Figure 1. 
LY2940094 (30 mg/kg, PO) significantly reduced continuous homecage ethanol (15% v/v) 
self-administration in Indiana Alcohol-Preferring (P) rats with a chronic history of high 
ethanol consumption at 3 (A) and 12 hr (B) post-treatment, without affecting food or water 
intake (C). The positive control, naltrexone (10 mg/kg, PO), significantly reduced ethanol 
self-administration at the 3 hr time point (A, gray bar), but failed to maintain efficacy after 
12 hr (B). The suppression of ethanol intake by LY2940094 did not show significant 
tolerance over 4 days of subchronic dosing (30 mg/kg, D). *, p < 0.05 vs. vehicle-treated 
rats.
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Figure 2. 
LY2940094 (30 mg/kg, PO) significantly and dose-dependently attenuated continuous 
ethanol (10% v/v) self-administration in Marchigian Sardinian Alcohol-Preferring (msP) rats 
at 2, 8, and 24 hr after dosing (A), without affecting food or water intake at any time point 
(B, C). *, p < 0.05 vs. vehicle-treated rats at the same time point; **, p < 0.01 vs. vehicle-
treated rats at the same time point.
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Figure 3. 
LY2940094 (30 mg/kg, PO) reduced the motivation to consume ethanol (as indicated by 
reduced breakpoints, A) and ethanol-seeking (B) in P rats maintained on a progressive ratio 
operant schedule. The positive control, naltrexone (10 mg/kg, PO), also significantly 
reduced ethanol motivation and ethanol-seeking (A,B). Values in A represent the highest 
fixed-ratio (FR) response requirement reached (breakpoint) during the 30-min session. 
Values in B represent the mean (+SEM) number of responses on the alcohol-associated 
lever. *, p < 0.05 vs. vehicle-treated rats.
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Figure 4. 
LY2940094 robustly blocked stress-induced reinstatement to ethanol-seeking in msP rats. 
Compared to extinction levels of responding, the anxiogenic agent and pharmacological 
stressor, yohimbine (2 mg/kg, IP), elicited a significant reinstatement to ethanol-seeking 
(white bar), and this effect was significantly reduced in rats receiving LY2940094 (3 or 30 
mg/kg; black bars). Values represent the mean (+SEM) number of responses on the alcohol-
associated lever. ##, p < 0.01 vs. responding during extinction; ***, p < 0.001 vs. vehicle-
treated rats receiving yohimbine (2 mg/kg, IP) during the reinstatement session.
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Figure 5. 
LY2940094 blocked ethanol-stimulated dopamine release in the Nucleus Accumbens. Main 
panel shows the time course of extracellular dopamine levels in response to ethanol 
challenge (1.1 g/kg, IP). Figure inset shows a summary of the mean extracellular dopamine 
levels in the 4 different treatment groups over the first 120 min after ethanol administration. 
Ethanol increased extracellular dopamine levels in the nucleus accumbens in rats receiving 
vehicle (“Vehicle + EtOH” group; open circles). Ethanol-stimulated increases in 
extracellular dopamine levels were prevented by pretreatment with 30 mg/kg LY2940094 
(“LY2940094 + EtOH” group; filled circles), which neither increased nor decreased 
extracellular dopamine levels when administered alone (“LY2940094 + Vehicle” group; gray 
squares). The blockade of ethanol-stimulated dopamine release in the nucleus accumbens is 
consistent with decreased ethanol self-administration and decreased motivation to consume 
ethanol. Values represent the mean (+SEM) concentration of extracellular dopamine in 
nucleus accumbens dialysate, as a percentage of the baseline concentration (average of three 
samples taken immediately prior to drug injection).
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